@article{1a908e0253764d2786e1556dfbe010fe,
title = "Paraneoplastic myelopathy with amphiphysin autoantibodies and lobular breast carcinoma in situ",
keywords = "Antibody, Breast cancer, Encephalomyelitis, Myelitis, Spinal cord",
author = "Alexandres, {Christina A.} and Tremblay, {Matthew A.} and Klassen, {Christine L.} and Amy Degnim and Flanagan, {Eoin P.}",
note = "Funding Information: Dr. Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH ( R01NS113828 ). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. Funding Information: Dr. Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH (R01NS113828). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports.",
year = "2022",
month = jan,
day = "15",
doi = "10.1016/j.jns.2021.120086",
language = "English (US)",
volume = "432",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
}